Lyn Jones is the Director of the Center for Protein Degradation at the Dana-Farber Cancer Institute. His research interests include the creation and application of chemistry-based technologies to advance therapeutic target identification and accelerate drug discovery. He is an elected fellow of the American Association for the Advancement of Science, the Royal Society of Chemistry, the Royal Society of Biology, and the Linnean Society, and serves on the editorial board of the journal RSC Medicinal Chemistry.
Lyn completed PhD studies in synthetic organic chemistry at the University of Nottingham, before starting his postdoctoral research at The Scripps Research Institute, California in the area of chemical biology. He joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader, eventually becoming Director of Chemical Biology and Lead Discovery Technologies. He transferred to Pfizer Cambridge, MA to become Head of Rare Disease Chemistry and Head of Chemical Biology. Lyn then joined Jnana Therapeutics as Vice President of Chemistry and Chemical Biology, before moving to his current role at DFCI.